Last updated: February 20, 2026
What is the drug identified by NDC 00904-6836?
NDC 00904-6836 corresponds to Emgality (galcanezumab-gnlm), a monoclonal antibody indicated for the prevention of migraine in adult patients. It is developed by Eli Lilly.
Current Market Position
Market Size and Growth
The migraine prophylaxis market is projected to reach $4 billion by 2025, growing at a compound annual growth rate (CAGR) of 8% (Source: IQVIA, 2022). Emgality captures a significant share of the branded migraine treatment market, competing against anti-epileptics, beta-blockers, and CGRP antagonists.
Competitive Landscape
Key competitors include:
- Aimovig (erenumab) by Amgen
- Ajovy (fremanezumab) by Teva
- Nurtec ODT (rimegepant) by Biohaven
Market Penetration
Since its approval in 2018, Emgality has secured a considerable share primarily through neurologist-prescribed therapy. Adoption rates are particularly high among patients with frequent migraines (>8 days/month).
Regulatory Status
- Approved by FDA in September 2018
- Approved in Europe in 2020
- Patent protection extends until at least 2032
Pricing Overview
Current Price Point
- Average wholesale price (AWP): approximately $645 per dose
- Per-year cost for a typical monthly injection (~12 doses/year): ~$7,740
Reimbursement and Coverage
- Majority of insurance plans cover Emgality
- Patient co-pay assistance programs reduce out-of-pocket costs to around $5-$10 per dose
Price Trends and Projections
Historical Price Trends
From 2018 to 2022, the wholesale price has increased approximately 2-3% annually, consistent with inflation and inflation-adjusted R&D cost recovery.
Future Price Projections (2023–2027)
| Year |
Estimated Wholesale Price per Dose |
Estimated Annual Cost |
Rationale |
| 2023 |
$650 |
$7,800 |
Slight inflation adjustment |
| 2024 |
$660 |
$7,920 |
Entry of biosimilars could pressure pricing |
| 2025 |
$670 |
$8,040 |
Patent protections remain, limited biosimilar impact |
| 2026 |
$680 |
$8,160 |
Biosimilar market entry potential may influence prices |
| 2027 |
$690 |
$8,280 |
Increased biosimilar competition expected |
Assumptions:
- Price growth restricted to inflation (approximately 1-2% annually)
- Patent protection held until 2032 limits biosimilar competition
- Biosimilar market entry begins in mid-2024, potentially exerting downward pressure starting 2025 onwards
Impact of Biosimilars
Entry of biosimilars, anticipated around 2024-2025, may reduce prices by 20-30%. Early biosimilar development suggests net savings but depends on regulatory approval and market acceptance.
Market Risks and Opportunities
Risks
- Biosimilar competition could halve prices within 2 years of market entry.
- Delays in approval or insurance coverage changes could reduce revenue.
- Patent litigation might extend exclusivity beyond 2032.
Opportunities
- Expanded indications (e.g., cluster headache, medication overuse headache) could grow market size.
- Geographic expansion into emerging markets could increase sales.
- Development of combination therapies might command premium pricing.
Final Considerations
Price projections rely on stable patent protections, continued market demand, and delayed biosimilar market entry. Price sensitivity among payers and patients remains significant. Market growth depends heavily on physician adoption and insurance reimbursement policies.
Key Takeaways
- Emgality's current wholesale price is approximately $645 per dose, with annual costs near $7,740.
- Market growth remains steady with anticipated expansion into new indications and geographies.
- Biosimilar entry around 2024-2025 is expected to exert downward pressure on prices.
- Prices are projected to grow modestly at 1-2% annually through 2027, barring biosimilar competition.
- Patent protections until 2032 sustain current pricing levels; patent litigation could alter this outlook.
FAQs
Q1: How might biosimilar entry affect Emgality’s pricing?
A: Biosimilars could reduce prices by 20-30% within 2 years of market entry, leading to lower healthcare costs but pressuring revenue.
Q2: Are there risks that could extend Emgality’s exclusivity?
A: Patent litigations could extend exclusivity beyond current projections, maintaining higher prices longer.
Q3: What is the typical patient out-of-pocket cost for Emgality?
A: With assistance, around $5–$10 per dose; without assistance, approximately $650 per dose.
Q4: How does Emgality compare in market share with competitors?
A: It holds a significant share among CGRP inhibitors but faces stiff competition from Aimovig and Ajovy.
Q5: Are there upcoming regulatory changes that could influence prices?
A: Approval of biosimilars and legislation on drug pricing could impact future costs, especially post-2024.
References
- IQVIA. (2022). Pharmaceutical Market Data.
- FDA. (2018). Emgality (galcanezumab-gnlm) Prescribing Information.
- European Medicines Agency. (2020). Emgality approval announcement.
- PhRMA. (2022). Biologics and Biosimilars Market Trends.
